BD111 not checked

Shanghai BDgene Co., Ltd. · HSV-1-erasing lentiviral particles

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.”In the company’s words, NCT06474442 on ClinicalTrials.gov
Tested for
Herpes Simplex Virus Type I Stromal Keratitis (2 trials)
Main trialPhase 2
“This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.”In the company’s words, NCT06474442 on ClinicalTrials.gov
Other names
HSV-1-erasing lentiviral particles · HELP

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Dec 2026 A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
Phase 1Active, not recruiting Oct 2025 A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BD111

Following is part of Solo: you see every change to BD111 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in